20/12/2013

1

HERACLES

KICK-OFF meeting 17-18 Dec 2013

The EC launched a SPECIFIC CALL (First Time!!) on the neglected infectious diseases.

20/12/2013

2

• THEME: HEALTH.2013.2.3.4-1: Neglected infectious diseases of Central and Eastern Europe

• FUNDING SCHEME: Collaborative Project (small-scale focused research project).

• THE AIM: establish an integrated approach for the development of preventive, therapeutic and diagnostic tools for NID. This action support innovative, collaborative biomedical research proposals. Focus on one or more viral, bacterial, protozoan, and/or helminthic human diseases.

• EXPECTED IMPACT: new knowledge about the biological mechanisms and pathology of NID.

H.E.R.A.C.L.E.S.

Human cystic Echinoccosis ReseArch in CentraL and Eastern Societies

GA: 602051 1st October, 2013 - 2017

20/12/2013

3

Countries of origin of HERACLES

20/12/2013

4

P. LEGAL NAME ACRONYM TYPE COUNTRY

1 ISTITUTO SUPERIORE DI SANITÀ ISS Research

Institute ITALY

2 UNIVERSITY OF PAVIA UNIPV Hospital

University ITALY

3 AGENCIA ESTATAL CONSEJO SUPERIOR DE

INVESTIGACIONES CIENTÍFICAS CSIC

Research

Institute SPAIN

4 SPITATUL CLINIC COLENTINA BUCURESTI CCHUMFCD Hospital

University ROMANIA

5 HACETTEPE UNIVERSITESI HUSMDR Hospital

University TURKEY

6

HOSPITAL FOR ACTIVE TREATMENT OF

INFECTIOUS AND PARASITIC DISEASES "PROF. I.

KIROV”

SHATIPD Hospital

University BULGARIA

7 MINISTRY OF FOOD AGRICOLTURE AND

LIVESTOCK PVCI

Research

Institute TURKEY

8 ALTA RICERCA E SVILUPPO IN BIOTECNOLOGIE

S.R.L.U. ALTA

Service-

provider

company

ITALY

9 VIRCELL S.L. VIRCELL Small Medium

Enterprise SPAIN

20/12/2013

5

Month Items Tentative

Location

2 Kick-Off meeting

(17-18/12/2013) Rome (Italy)

12 2° meeting Ankara (Turkey)

24 3° meeting Bucharest (Romania)

36 4° meeting Sofia (Bulgaria)

48 Final meeting Rome (Italy)

MEETING SCHEDULE

Scheme of HERACLES management

G.A. C.A.

20/12/2013

6

The main OBJECTIVES of HERACLES are:

- Identify by ultrasound screening the population affected by CE;

- Create EE national registry for the surveillance of CE to provide baseline data for risk calculations and to establish a prospective case retrieval;

- Establish a Bio-Bank from animal and human CE patients and related Databases;

- Validate new molecular-based POC-LOC kits for immunological surveillance, rapid diagnosis and follow-up in humans and animals;

- Identify molecular base/s associated with CE response to therapy or lack thereof through host-parasite interplay;

- Increase drug bioavailability in an in vivo model and to synthesize a new enantiomeric drug based on ABZ.

WP1

WP2 WP3

CE ultrasound screeening

EE registry

Host-parasite interplay

BioBank (databases)

new molecular based tools

Enantiomeric drug developing

WP4

Training and dissemination

WP5

Management and IPR

WP6

20/12/2013

7

MANAGEMENT and IPR (WP6)

TRAINING and DISSEMINATION (WP5)

ULTRASOUND SCREENING (WP1)

HERACLES WORKFLOW

VALIDATION of MOLECULAR TOOLS

(WP2)

BIO-BANK (WP2)

COMMERCIAL POC-LOC KIT (WP2)

ANIMAL SAMPLES COLLECTION (WP4)

ABZ BIOAVAILABILITY and ENANTIOMERIC

DRUG SYNTHESIS (WP4)

IN VIVO ANIMAL MODEL (WP4)

HOST-PARASITE INTERPLAY (WP3)

EE REGISTRY (WP1)

HUMAN SAMPLES COLLECTION (WP1)

HOSPITALS NETWORK (WP1)

ULTRASOUND SCREENING and CE NATIONAL REGISTRIES - WP1

Task 1.1: Survey statistical assessment Task 1.2: Ultrasound Survey Task 1.3: Human sample collection Task 1.4: EE registries

20/12/2013

8

NEW MOLECULAR-BASED TOOLS – WP2

Task 2.1: Sample Repository Task 2.2: Database development Task 2.3: Production and testing recombinant antigens Task 2.4: Development of POC-LOC devices

HOST-PARASITE INTERPLAY – WP3

Task 3.1: Genotypic characterization (Parasite) Task 3.2: HLA class I and II polymorphisms (Human) Task 3.3: KIR gene polymorphisms (Human) Task 3.4: HLA-G polymorphism (Human) Task 3.5: Proteomic analysis (Human) Task 3.6: Transcriptome analysis (Parasite)

(parasite virulence vs human immunity)

20/12/2013

9

BIOAVAILABILITY of ABZ and ENANTIOMERIC DRUG SYNTHESIS – WP4

Task 4.1: Animal sample collection Task 4.2: Parasite collection and drug formulations Task 4.3: Experimental design in the animal model Task 4.4: Necropsy and sample collection Task 4.5: Pharmacokinetics and Toxicology Task 4.6: Statistical analysis and new drug synthesis

Infection

Experiments

Drug bioavailability

Parasite viability

Toxicology

TRAINING and DISSEMINATION – WP5

Task 5.1: Dissemination of results a) EU citizens

b) experts c) public health authorities, policy makers

Task 5.2: Training a) staff exchange b) ultrasound on CE, PAIR and related techniques, genotyping c) educational events

Task 5.3: Exploitation of the project results

20/12/2013

10

Task 6.1: Set up of project structure and activities Task 6.2: Administrative Management Task 6.3: IPR Task 6.4: Ethics Management

MANAGEMENT and IPR – WP6

Thank you!

......is growing!